Cadrenal Therapeutics (NASDAQ:CVKD) Releases Earnings Results, Misses Estimates By $1.03 EPS

Cadrenal Therapeutics (NASDAQ:CVKD) issued its earnings results on Thursday. The company reported ($2.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.71) by ($1.03), Zacks reports.

Cadrenal Therapeutics Trading Up 9.4 %

Shares of CVKD opened at $19.09 on Friday. Cadrenal Therapeutics has a 1 year low of $5.40 and a 1 year high of $22.90. The stock has a 50 day simple moving average of $18.31 and a 200-day simple moving average of $15.03. The stock has a market cap of $34.04 million, a PE ratio of -2.86 and a beta of 1.40.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.